Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Procter & Gamble

Latest From Procter & Gamble

US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Consumer Business Strategies

Menopause And Women’s Health Prominent Among Recent German OTC Launches

Responding to demand from women for consumer health products that meet their specific needs, P&G and Pro Medico both launch hop-based supplements for menopause symptoms. Meanwhile, Bayer adds a hair mask to its Priorin range for women with female pattern hair loss and Klosterfrau expands its Femafriends brand with an intimate health gel.

Germany Health

Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak

South Korea’s clinical trial approvals rebounded in 2023, but remained lower than the peak levels in 2020-21 amid then robust R&D activity related to COVID-19. Last year's tally showed a mix of single-country and multinational trials and reflected the ongoing dominance of oncology in industry pipelines.

South Korea Clinical Trials

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Sales & Earnings OTC Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer